Indication
Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Loading your page…
Loading your page…
Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis
Marketing Authorisation Holder: Neuraxpharm Pharmaceuticals S.L.
EMA Authorisation: 31/05/2023
INN: ublituximab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Briumvi: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.